Orano Med
Tania Stallons, Ph.D., serves as the Associate Director of CMC and Principal Scientist at Orano Med since June 2014, leading R&D studies to advance ²¹²Pb-based therapeutic development from preclinical phases to Phase II, while overseeing CMC-related studies and regulatory submissions. Previously, Tania held the position of Scientist at AREVA Med, contributing to the development of innovative cancer therapies. Prior experience includes a Research Associate role at Scripps Research, focusing on the mechanisms of genotoxic stress and aging, and a Doctoral Student position at Florida Institute of Technology, where Tania explored DNA-protein interactions in bacterial cell cycle regulation. Tania has also worked as a National Science Foundation GK-12 Fellow, engaging high school students and the community in scientific education. Tania earned a Ph.D. and a Bachelor of Science in Molecular Biology from Florida Institute of Technology.
This person is not in any teams
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.